Company news

Clarity Pharmaceuticals Ltd. news in 2023

Clarity Pharmaceuticals Ltd.'s news releases, calls and decks from 2023, newest first.

View company

First patient dosed in Phase III prostate cancer trial

December 21, 2023

Recruitment closes for a diagnostic Phase II trial in NETs

December 18, 2023

Phase III CLARIFY trial in prostate cancer commences

November 29, 2023

undetectable PSA level with Cu-67 SAR-bisPSMA

November 29, 2023

SECuRE theranostic prostate cancer trial progresses

November 29, 2023

Bell Potter Healthcare Conference Presentation

November 14, 2023

Recruitment target achieved for Phase II SAR-Bombesin trial

November 6, 2023

Presentation for Wilsons Drug and Device Conference

October 26, 2023

First patient treated with Cu-67 SAR-Bombesin

October 2, 2023

Company Presentation E&P Small Cap Healthcare Conference

September 12, 2023

BOP preliminary trial results presented at EANM 2023

September 12, 2023

First neuroblastoma participant treated in highest cohort

August 25, 2023

First PC participant treated at the highest dose level

August 24, 2023

Theranostic prostate cancer trial advances to cohort 3

August 9, 2023

Clarity Bolsters Antibody Pre-Targeting with IP from MSK

August 6, 2023

Final Cohort opens for CL04 Paediatric Neuroblastoma trial

July 25, 2023

Phase II SABRE prostate cancer trial reaches 50% recruitment

July 23, 2023

Positive Guidance from FDA on Phase 3 Prostate Cancer Trial

July 3, 2023

Clarity Establishes US Center of Excellence for Research

June 27, 2023

Northstar Achieves Key Production Milestones

June 26, 2023

COMBAT theranostic prostate cancer trial commences in the US

June 19, 2023

Clarity expands supply of Cu-64 for Phase III trials

June 13, 2023

Presentation at Jefferies Healthcare Conference

June 12, 2023

Recruitment complete for Phase II prostate cancer trial

June 6, 2023

Theranostic prostate cancer trial advances to cohort 2

May 24, 2023

Clarity Receives $6.7 million R&D Tax Incentive Refund

April 18, 2023

Clarity Corporate Presentation

March 13, 2023

50% recruitment milestone for NET diagnostic Phase II trial

February 15, 2023

PROPELLER Trial Results

February 13, 2023

Diagnostic prostate cancer trial reaches recruitment target

February 8, 2023

Decks in 2023